<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00934934</url>
  </required_header>
  <id_info>
    <org_study_id>CANTREAT</org_study_id>
    <nct_id>NCT00934934</nct_id>
  </id_info>
  <brief_title>Candida in the Respiratory Tract Secretions of Critically Ill Patients and The Efficacy of Antifungal Treatment</brief_title>
  <acronym>CANTREAT</acronym>
  <official_title>Candida in the Respiratory Tract Secretions of Critically Ill Patients and The Efficacy of Antifungal Treatment (The CANTREAT Study): A Prospective, Randomized, Double Blind, Placebo Controlled Pilot Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Daren K. Heyland</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>The Physicians' Services Incorporated Foundation</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Queen's University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Pfizer</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Clinical Evaluation Research Unit at Kingston General Hospital</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of the study is to determine whether the effect of treating Candida spp. isolated
      in the respiratory tract secretions of patients with a clinical suspicion of ventilator
      associated pneumonia (VAP) on clinical outcomes will be feasible and supported by biomarker
      data obtained.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Candida spp. is commonly retrieved from microbiologic specimens of ICU patients with
      suspected VAP. It has been associated with increased systemic inflammation and worse clinical
      outcomes. This association may be due to the propensity for Candida to colonize those who are
      sicker, who have increased levels of systemic inflammation and worse clinical outcomes.
      However, an alternate possibility is that Candida is more than a colonizer and is responsible
      for the clinical and biochemical features observed. The only way to clarify the pathogenic
      role of Candida from this patient population is to treat the organism and see if patients
      improve compared to an untreated group. The purpose of this research program is to conduct
      such a study to determine if Candida in respiratory tract secretions should be routinely
      treated in critically ill patients. Since a definitive randomized controlled trial designed
      to demonstrate a reduction in mortality would be large, require the commitment of large
      amount of resources including both time and money, the investigators propose to first conduct
      a small pilot feasibility study.

      Eligible patients will be randomized to receive antifungal treatment with anidulafungin or
      placebo. Following enrollment, study treatment (or placebo) will be started as soon as
      possible. When the Candida or yeast organisms have been speciated and/or a susceptibility
      profile is known, the study medication will be adjusted based on susceptibility patterns. The
      investigators propose to treat with antifungal therapy for a total of 14 days.

      Patients will be followed daily for their entire stay in ICU or till day 28, whichever comes
      first. For patients discharged from the ICU to the ward, they will be followed until study
      treatment is complete (i.e. day 14). Mortality will be determined for the ICU stay, hospital
      stay and at 90 days. The investigators will record admission and discharge dates to ICU, step
      down units, and to hospital.

      All patients will have 13 mL of blood/day drawn at baseline, day 3, day 8 and at the end of
      the treatment period on day 14 (or last day of treatment). The samples will be prepared on
      site and shipped to a central lab for processing. The investigators will use the blood
      specimens to measure markers of inflammation (C-reactive protein, Procalcitonin, and
      Interleukin-6 and others as determined by the investigators), markers of candida presence
      (b-glucan and other potential future markers) and markers of immune dysfunction (to be
      determined by investigators).
    </textblock>
  </detailed_description>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    slow enrollment
  </why_stopped>
  <start_date>April 2010</start_date>
  <completion_date type="Actual">August 2012</completion_date>
  <primary_completion_date type="Actual">August 2012</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Other</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Feasibility will be assessed as follows: 1) Recruitment rates; 2) time required to capture required data; 3) acceptability of treatment protocol and requirement for open-label antifungal agents; 4)acceptability of laboratory procedures.</measure>
    <time_frame>32 months</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Duration of stay in ICU</measure>
    <time_frame>32 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Adjudicated diagnosis of superinfection</measure>
    <time_frame>32 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Acquired resistance to antifungal therapy</measure>
    <time_frame>32 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Ventilator free days</measure>
    <time_frame>32 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>ICU free days</measure>
    <time_frame>32 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Antibiotic free days 28-day post randomization</measure>
    <time_frame>32 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Hospital length of stay (hospital survival and 90 day mortality)</measure>
    <time_frame>32 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in organ function as measured by Sequential Organ Failure Assessment (COFA) post randomization</measure>
    <time_frame>32 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Sequential procalcitonin, C-reactive protein, interleukin-6 and B-glucan levels</measure>
    <time_frame>32 months</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">60</enrollment>
  <condition>Ventilator Associated Pneumonia</condition>
  <condition>Respiratory Tract Infection</condition>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Saline will serve as the placebo solution since the active comparator is clear and colourless.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Antifungal</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Patient will receive a dose daily for a total of 14 days</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Normal Saline</intervention_name>
    <description>Normal Saline</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>anidulafungin</intervention_name>
    <description>TBA</description>
    <arm_group_label>Antifungal</arm_group_label>
    <other_name>TBA</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Adult patients (&gt;18 years old)

          2. In the ICU &gt; 48 hours

          3. Mechanically ventilated (&gt;48 hours)

          4. Grow a Candida spp. on respiratory tract secretion culture (either by Bronchoalveolar
             Lavage or Endotracheal Aspirate) taken on or between 48 hours before or after the day
             of their suspicion of respiratory tract infection.

          5. Develop a clinical suspicion of respiratory tract infection while ventilated as
             defined by the following criteria (as defined previously in our VAP trial)5:

               -  The presence of new, worsening or persistent radiographic features suggestive of
                  pneumonia without another obvious cause AND

               -  The presence of any two of the following:

                    -  Fever &gt; 38C (core temperature)

                    -  Leukocytosis (&gt;11.0 x109/L) or neutropenia (&lt;3.5 x109/L)

                    -  Purulent endotracheal aspirates or change in character of aspirates

                    -  Isolation of pathogenic bacteria from endotracheal aspirates

                    -  Increasing oxygen requirements

        Exclusion Criteria:

          1. Patients not expected to be in ICU for more than 72 hours (due to imminent death,
             withdrawal of aggressive care or discharge).

          2. Patients with Candida spp. in the blood or another sterile body site.

          3. Patients colonized at other non-pulmonary body site(s) with Candida.

          4. Already being treated with antifungal drugs (because of documented fungal infection,
             pre-emptive therapy, or prophylaxis).

          5. Allergy to study drugs (Fluconazole or the Echinocandin on formulary at treating
             institution).

          6. Immunocompromised patients (post-organ transplantation, Acquired Immunodeficiency
             Syndrome [AIDS], neutropenia [&lt;1000 absolute neutrophils], corticosteroids [&gt;20
             mgs/day of prednisone or equivalent for more than 6 months]). These patients are
             excluded since Candida may be more invasive and these patients are much more likely to
             require systemic antifungal therapy.

          7. Patients with fulminant liver failure or end stage liver disease (Child's Class C).

          8. Women who are pregnant or lactating.

          9. Enrollment in industry sponsored interventional trial (co-enrollment in other academic
             studies would be allowed with the proviso that there was no potential interaction
             between the protocols).

         10. Prior randomization in this study.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Daren Heyland, MD</last_name>
    <role>Study Chair</role>
    <affiliation>Clinical Evaluation Research Unit</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Hamilton Health Sciences Centre</name>
      <address>
        <city>Hamilton</city>
        <state>Ontario</state>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Kingston General Hospital</name>
      <address>
        <city>Kingston</city>
        <state>Ontario</state>
        <zip>K7L 2V7</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ottawa General Hospital</name>
      <address>
        <city>Ottawa</city>
        <state>Ontario</state>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hopital Maisonneuve-Rosemont</name>
      <address>
        <city>Montreal</city>
        <state>Quebec</state>
        <zip>H1T 2M4</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hopital du Sacre-Coeur do Montreal</name>
      <address>
        <city>Montreal</city>
        <state>Quebec</state>
        <zip>H4J 1C5</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hopital l'Enfant-Jesus</name>
      <address>
        <city>Quebec</city>
        <zip>G1J 1Z4</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Canada</country>
  </location_countries>
  <reference>
    <citation>Safdar N, Dezfulian C, Collard HR, Saint S. Clinical and economic consequences of ventilator-associated pneumonia: a systematic review. Crit Care Med. 2005 Oct;33(10):2184-93. Review.</citation>
    <PMID>16215368</PMID>
  </reference>
  <reference>
    <citation>Muscedere JG, Martin CM, Heyland DK. The impact of ventilator-associated pneumonia on the Canadian health care system. J Crit Care. 2008 Mar;23(1):5-10. doi: 10.1016/j.jcrc.2007.11.012. Review.</citation>
    <PMID>18359415</PMID>
  </reference>
  <reference>
    <citation>Van Saene H., Peric M., De La Cal M., Silvestri L.: Pneumonia during Mechanical Ventilation. Anestiologie a Intenzivni Medicina 2004; 15: 89-100.</citation>
  </reference>
  <reference>
    <citation>Chastre J, Fagon JY. Ventilator-associated pneumonia. Am J Respir Crit Care Med. 2002 Apr 1;165(7):867-903. Review.</citation>
    <PMID>11934711</PMID>
  </reference>
  <reference>
    <citation>Canadian Critical Care Trials Group. A randomized trial of diagnostic techniques for ventilator-associated pneumonia. N Engl J Med. 2006 Dec 21;355(25):2619-30.</citation>
    <PMID>17182987</PMID>
  </reference>
  <reference>
    <citation>Heyland DK, Dodek P, Muscedere J, Day A, Cook D; Canadian Critical Care Trials Group. Randomized trial of combination versus monotherapy for the empiric treatment of suspected ventilator-associated pneumonia. Crit Care Med. 2008 Mar;36(3):737-44.</citation>
    <PMID>18091545</PMID>
  </reference>
  <reference>
    <citation>Muscedere J, Dodek P, Keenan S, Fowler R, Cook D, Heyland D; VAP Guidelines Committee and the Canadian Critical Care Trials Group. Comprehensive evidence-based clinical practice guidelines for ventilator-associated pneumonia: prevention. J Crit Care. 2008 Mar;23(1):126-37. doi: 10.1016/j.jcrc.2007.11.014.</citation>
    <PMID>18359430</PMID>
  </reference>
  <reference>
    <citation>Muscedere J, Dodek P, Keenan S, Fowler R, Cook D, Heyland D; VAP Guidelines Committee and the Canadian Critical Care Trials Group. Comprehensive evidence-based clinical practice guidelines for ventilator-associated pneumonia: diagnosis and treatment. J Crit Care. 2008 Mar;23(1):138-47. doi: 10.1016/j.jcrc.2007.12.008.</citation>
    <PMID>18359431</PMID>
  </reference>
  <reference>
    <citation>Muscedere JG, McColl C, Shorr A, Jiang X, Marshall J, Heyland DK; Canadian Critical Care Trials Group. Determinants of outcome in patients with a clinical suspicion of ventilator-associated pneumonia. J Crit Care. 2008 Mar;23(1):41-9. doi: 10.1016/j.jcrc.2007.12.007.</citation>
    <PMID>18359420</PMID>
  </reference>
  <reference>
    <citation>Rello J, Esandi ME, Díaz E, Mariscal D, Gallego M, Vallès J. The role of Candida sp isolated from bronchoscopic samples in nonneutropenic patients. Chest. 1998 Jul;114(1):146-9.</citation>
    <PMID>9674461</PMID>
  </reference>
  <reference>
    <citation>el-Ebiary M, Torres A, Fàbregas N, de la Bellacasa JP, González J, Ramirez J, del Baño D, Hernández C, Jiménez de Anta MT. Significance of the isolation of Candida species from respiratory samples in critically ill, non-neutropenic patients. An immediate postmortem histologic study. Am J Respir Crit Care Med. 1997 Aug;156(2 Pt 1):583-90.</citation>
    <PMID>9279244</PMID>
  </reference>
  <reference>
    <citation>Senn L, Robinson JO, Schmidt S, Knaup M, Asahi N, Satomura S, Matsuura S, Duvoisin B, Bille J, Calandra T, Marchetti O. 1,3-Beta-D-glucan antigenemia for early diagnosis of invasive fungal infections in neutropenic patients with acute leukemia. Clin Infect Dis. 2008 Mar 15;46(6):878-85. doi: 10.1086/527382.</citation>
    <PMID>18260755</PMID>
  </reference>
  <reference>
    <citation>Odabasi Z, Mattiuzzi G, Estey E, Kantarjian H, Saeki F, Ridge RJ, Ketchum PA, Finkelman MA, Rex JH, Ostrosky-Zeichner L. Beta-D-glucan as a diagnostic adjunct for invasive fungal infections: validation, cutoff development, and performance in patients with acute myelogenous leukemia and myelodysplastic syndrome. Clin Infect Dis. 2004 Jul 15;39(2):199-205. Epub 2004 Jun 28.</citation>
    <PMID>15307029</PMID>
  </reference>
  <reference>
    <citation>Wheeler RT, Fink GR. A drug-sensitive genetic network masks fungi from the immune system. PLoS Pathog. 2006 Apr;2(4):e35. Epub 2006 Apr 28.</citation>
    <PMID>16652171</PMID>
  </reference>
  <reference>
    <citation>Azoulay E, Timsit JF, Tafflet M, de Lassence A, Darmon M, Zahar JR, Adrie C, Garrouste-Orgeas M, Cohen Y, Mourvillier B, Schlemmer B; Outcomerea Study Group. Candida colonization of the respiratory tract and subsequent pseudomonas ventilator-associated pneumonia. Chest. 2006 Jan;129(1):110-7.</citation>
    <PMID>16424420</PMID>
  </reference>
  <reference>
    <citation>Delisle MS, Williamson DR, Perreault MM, Albert M, Jiang X, Heyland DK. The clinical significance of Candida colonization of respiratory tract secretions in critically ill patients. J Crit Care. 2008 Mar;23(1):11-7. doi: 10.1016/j.jcrc.2008.01.005.</citation>
    <PMID>18359416</PMID>
  </reference>
  <reference>
    <citation>Heyland et al, WATTCH database. Observational study of the clinical characteristics and biomarker profiles of 569 critically ill patients. Analysis ongoing.</citation>
  </reference>
  <reference>
    <citation>Williamson D., Martin A., Perreault M., Delisle M., Muscedere J., Rotstein C., Jiang X., Heyland D. Impact of pulmonary Candida colonization on systemic inflammation in the critically ill. Manuscript in preparation.</citation>
  </reference>
  <reference>
    <citation>Magill SS, Swoboda SM, Johnson EA, Merz WG, Pelz RK, Lipsett PA, Hendrix CW. The association between anatomic site of Candida colonization, invasive candidiasis, and mortality in critically ill surgical patients. Diagn Microbiol Infect Dis. 2006 Aug;55(4):293-301. Epub 2006 May 15. Erratum in: Diagn Microbiol Infect Dis. 2007 Mar;57(3):351.</citation>
    <PMID>16698215</PMID>
  </reference>
  <reference>
    <citation>Müller V, Viemann D, Schmidt M, Endres N, Ludwig S, Leverkus M, Roth J, Goebeler M. Candida albicans triggers activation of distinct signaling pathways to establish a proinflammatory gene expression program in primary human endothelial cells. J Immunol. 2007 Dec 15;179(12):8435-45.</citation>
    <PMID>18056390</PMID>
  </reference>
  <reference>
    <citation>Inoue K, Takano H, Oda T, Yanagisawa R, Tamura H, Ohno N, Adachi Y, Ishibashi K, Yoshikawa T. Candida soluble cell wall beta-D-glucan induces lung inflammation in mice. Int J Immunopathol Pharmacol. 2007 Jul-Sep;20(3):499-508.</citation>
    <PMID>17880763</PMID>
  </reference>
  <reference>
    <citation>Sakurai T, Ohno N, Yadomae T. Effects of fungal beta-glucan and interferon-gamma on the secretory functions of murine alveolar macrophages. J Leukoc Biol. 1996 Jul;60(1):118-24.</citation>
    <PMID>8699115</PMID>
  </reference>
  <reference>
    <citation>Nseir S, Jozefowicz E, Cavestri B, Sendid B, Di Pompeo C, Dewavrin F, Favory R, Roussel-Delvallez M, Durocher A. Impact of antifungal treatment on Candida-Pseudomonas interaction: a preliminary retrospective case-control study. Intensive Care Med. 2007 Jan;33(1):137-42. Epub 2006 Nov 8.</citation>
    <PMID>17115135</PMID>
  </reference>
  <reference>
    <citation>Tschaikowsky K, Hedwig-Geissing M, Schiele A, Bremer F, Schywalsky M, Schüttler J. Coincidence of pro- and anti-inflammatory responses in the early phase of severe sepsis: Longitudinal study of mononuclear histocompatibility leukocyte antigen-DR expression, procalcitonin, C-reactive protein, and changes in T-cell subsets in septic and postoperative patients. Crit Care Med. 2002 May;30(5):1015-23.</citation>
    <PMID>12006796</PMID>
  </reference>
  <reference>
    <citation>Williamson D., Albert M., Perreault M., Delisle M., Muscedere J., Rotstein C.Jiang X., Day A. ,Heyland D. Effect of Candida spp. in respiratory tract secretions on systemic inflammation. Submitted to SCCM for Feb. 2009</citation>
  </reference>
  <reference>
    <citation>Presterl E, Lassnigg A, Mueller-Uri P, El-Menyawi I, Graninger W. Cytokines in sepsis due to Candida albicans and in bacterial sepsis. Eur Cytokine Netw. 1999 Sep;10(3):423-30.</citation>
    <PMID>10477399</PMID>
  </reference>
  <reference>
    <citation>Christofilopoulou S, Charvalos E, Petrikkos G. Could procalcitonin be a predictive biological marker in systemic fungal infections?. Study of 14 cases. Eur J Intern Med. 2002 Dec;13(8):493-495.</citation>
    <PMID>12446193</PMID>
  </reference>
  <reference>
    <citation>Reade MC, Angus DC. The clinical research enterprise in critical care: what's right, what's wrong, and what's ahead? Crit Care Med. 2009 Jan;37(1 Suppl):S1-9. doi: 10.1097/CCM.0b013e318192074c.</citation>
    <PMID>19104206</PMID>
  </reference>
  <reference>
    <citation>van Teijlingen E, Hundley V. The importance of pilot studies. Nurs Stand. 2002 Jun 19-25;16(40):33-6. Review.</citation>
    <PMID>12216297</PMID>
  </reference>
  <reference>
    <citation>Arnold DM, Burns KE, Adhikari NK, Kho ME, Meade MO, Cook DJ; McMaster Critical Care Interest Group. The design and interpretation of pilot trials in clinical research in critical care. Crit Care Med. 2009 Jan;37(1 Suppl):S69-74. doi: 10.1097/CCM.0b013e3181920e33. Review.</citation>
    <PMID>19104228</PMID>
  </reference>
  <reference>
    <citation>Canadian Institutes of Health Research. Available at: www.cihr.ca Accessed February 9, 2009.</citation>
  </reference>
  <verification_date>January 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>July 7, 2009</study_first_submitted>
  <study_first_submitted_qc>July 7, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 8, 2009</study_first_posted>
  <last_update_submitted>January 24, 2018</last_update_submitted>
  <last_update_submitted_qc>January 24, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">January 26, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>Clinical Evaluation Research Unit at Kingston General Hospital</investigator_affiliation>
    <investigator_full_name>Daren K. Heyland</investigator_full_name>
    <investigator_title>Director, Clinical Evaluation Research Unit</investigator_title>
  </responsible_party>
  <keyword>Candida</keyword>
  <keyword>ventilator associated pneumonia</keyword>
  <keyword>respiratory tract infection</keyword>
  <keyword>antifungal</keyword>
  <keyword>biomarker</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Pneumonia</mesh_term>
    <mesh_term>Critical Illness</mesh_term>
    <mesh_term>Respiratory Tract Infections</mesh_term>
    <mesh_term>Pneumonia, Ventilator-Associated</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Antifungal Agents</mesh_term>
    <mesh_term>Miconazole</mesh_term>
    <mesh_term>Anidulafungin</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

